Contineum Therapeutics Advances PIPE-791 Phase 2 Trial for Idiopathic Pulmonary Fibrosis with Differentiated LPA1 Receptor Targeting
核心洞察
Contineum Therapeutics has initiated patient dosing in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for idiopathic pulmonary fibrosis (搜索), targeting 324 patients over 26 weeks with a primary endpoint of forced vital capacity change.
PIPE-791 demonstrates potential differentiation from Bristol Myers Squibb (搜索)'s competing LPA1 antagonist through achieving approximately 90% receptor occupancy at 1 mg daily dosing and showing no hypotension signal to date.
The company maintains financial runway through mid-2029 following a $93 million public offering, while also advancing PIPE-307 in partnership with Johnson & Johnson for major depressive disorder (搜索) treatment.
Contineum Therapeutics has initiated patient dosing in its pivotal Phase 2 clinical trial evaluating PIPE-791 for idiopathic pulmonary fibrosis (搜索) (IPF), marking a significant milestone for the clinical-stage biopharmaceutical company as it advances what management believes could be a best-in-class LPA1 receptor (搜索) antagonist.
The PROPEL-IPF trial represents a 26-week, randomized, double-blind, placebo-controlled study targeting approximately 324 IPF patients globally. The primary efficacy endpoint focuses on change from baseline through week 26 in absolute forced vital capacity (FVC mL), a critical measure of lung function in this devastating disease.
Differentiated Approach to LPA1 Targeting
CEO Carmine Stengone positioned PIPE-791 as potentially transformative for IPF treatment, emphasizing its differentiated profile compared to existing therapies. "PIPE-791 may potentially offer an improved dosing, efficacy and tolerability profile to enable sustainable management of this unrelenting disease," Stengone stated.
The company's leadership highlighted several key differentiators for PIPE-791 versus Bristol Myers Squibb (搜索)'s competing LPA1 receptor (搜索) antagonist zimilparant (搜索). Chief Medical Officer Tim Watkins noted that PIPE-791 can achieve approximately 90% receptor occupancy at doses as low as 1 mg daily, suggesting superior target coverage compared to Bristol Myers Squibb's pharmacokinetic profile.
Additionally, Contineum emphasized PIPE-791's once-daily dosing convenience, which could prove important for the typically older IPF patient population. The company also reported no observed hypotension signal in studies to date, contrasting with Bristol Myers Squibb (搜索)'s noted hypotension concerns that have led to dose titration strategies in their Phase 3 program.
Rigorous Trial Design and Execution Focus
Watkins described the ongoing Phase 2 IPF study as "phase III-like in rigor," though not in size. The 108-subject trial features three arms including placebo and two PIPE-791 dose arms over 26 weeks, allowing background therapy. The company has emphasized operational excellence, particularly in investigator training, IPF diagnosis confirmation against guideline criteria, and ensuring high-quality spirometry and FVC measurement.
If PIPE-791 demonstrates good tolerability, Contineum envisions it as a potential "foundation" therapy that may be easier to combine with other agents than current marketed IPF drugs, noting that combinations could prove important since existing therapies slow rather than stop disease progression.
Expanding Clinical Portfolio and Partnership Success
Beyond IPF, Contineum anticipates reporting topline data from its exploratory PIPE-791 Phase 1b trial in patients with chronic osteoarthritis pain (搜索) or chronic lower back pain (搜索) in the second quarter of 2026. This randomized, double-blind, placebo-controlled, crossover trial initiated patient dosing in March 2025.
The company's partnership with Johnson & Johnson continues to advance PIPE-307, a selective M1 receptor (搜索) inhibitor, in major depressive disorder (搜索). Johnson & Johnson began recruiting an estimated 124 adult participants for the Phase 2 Moonlight-1 trial in December 2024, evaluating PIPE-307/JNJ-89495120 as monotherapy with a primary endpoint of change in MADRS on day five.
The 2023 Johnson & Johnson collaboration delivered substantial value, including a $50 million upfront payment, $25 million equity investment, more than $1 billion in potential milestones across development, regulatory, and commercial events, and royalties starting in the low teens and ramping to the high teens.
Strong Financial Position Supports Development
Contineum reported cash, cash equivalents and marketable securities of $262.9 million as of December 31, 2025, following completion of an upsized public offering that generated net proceeds of $93.0 million from approximately 8.1 million shares at $12.25 per share. The company believes its cash resources are sufficient to fund planned operations through mid-2029, approximately one year past the estimated completion of the IPF trial.
Research and development expenses decreased 2% to $12.8 million in the fourth quarter, primarily due to completion of the PIPE-307 VISTA trial and lower CTX-343 program costs, partially offset by increased PIPE-791 program expenses. Net loss was $15.2 million for the quarter compared to $14.6 million in the prior year.
Market Validation and Competitive Landscape
Management views Bristol Myers Squibb (搜索)'s expected Phase 3 IPF data for zimilparant (搜索) in Q4 2026 as an important external validation event for the LPA1 target class. Stengone cited prior Bristol Myers Squibb readouts in progressive pulmonary fibrosis (搜索) and IPF across two molecules as strong validation of the target mechanism.
The company continues operating an internal discovery engine while acknowledging that clinical development will consume the majority of capital allocation going forward. Stengone noted that while Contineum speaks with strategic partners frequently, the company does not foresee a near-term partnership deal, preferring to generate additional PIPE-791 IPF data first.